Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the SHR-4595 injection, issued by the National Medical Products Administration. The clinical trials are scheduled to commence in the near future.

The SHR-4595 injection is a therapeutic biological product independently developed by the company, designed to specifically bind to antigens on the surface of tumor cells to eliminate them, targeting the treatment of advanced malignant solid tumors. According to available data, one drug using the same target has already been approved and marketed both domestically and internationally.

As of now, the cumulative research and development investment in the SHR-4595-related projects amounts to approximately RMB 16.4 million (unaudited).